tetano
Editor, Senior Moderator
Biomedicines
. 2022 Jan 13;10(1):171.
doi: 10.3390/biomedicines10010171.
Humoral Immune Response in IBD Patients Three and Six Months after Vaccination with the SARS-CoV-2 mRNA Vaccines mRNA-1273 and BNT162b2
Richard Vollenberg[SUP] 1 [/SUP], Phil-Robin Tepasse[SUP] 1 [/SUP], Joachim Ewald Kühn[SUP] 2 [/SUP], Marc Hennies[SUP] 2 [/SUP], Markus Strauss[SUP] 3 [/SUP], Florian Rennebaum[SUP] 1 [/SUP], Tina Schomacher[SUP] 1 [/SUP], Göran Boeckel[SUP] 4 [/SUP], Eva Lorentzen[SUP] 2 [/SUP], Arne Bokemeyer[SUP] 5 [/SUP], Tobias Max Nowacki[SUP] 1 6 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronovirus-2 (SARS-CoV-2) is the cause of the coronavirus disease 2019 (COVID-19) pandemic. Vaccination is considered the core approach to containing the pandemic. There is currently insufficient evidence on the efficacy of these vaccines in immunosuppressed inflammatory bowel disease (IBD) patients. The aim of this study was to investigate the humoral response in immunosuppressed IBD patients after COVID-19 mRNA vaccination. In this prospective study, IgG antibody levels (AB) against the SARS-CoV-2 receptor-binding domain (spike-protein) were quantitatively determined. For assessing the potential neutralizing capacity, a SARS-CoV-2 surrogate neutralization test (sVNT) was employed in IBD patients (n = 95) and healthy controls (n = 38). Sera were examined prior to the first/second vaccination and 3/6 months after second vaccination. Patients showed lower sVNT (%) and IgG-S (AU/mL) AB both before the second vaccination (sVNT p < 0.001; AB p < 0.001) and 3 (sVNT p = 0.002; AB p = 0.001) and 6 months (sVNT p = 0.062; AB p = 0.061) after the second vaccination. Although seroconversion rates (sVNT, IgG-S) did not differ between the two groups 3 months after second vaccination, a significant difference was seen 6 months after second vaccination (sVNT p = 0.045). Before and three months after the second vaccination, patients treated with anti-tumor necrosis factor (TNF) agents showed significantly lower AB than healthy subjects. In conclusion, an early booster shot vaccination should be discussed for IBD patients on anti-TNF therapy.
Keywords: COVID-19; IBD patients; SARS-CoV-2; seroconversion; vaccination.
. 2022 Jan 13;10(1):171.
doi: 10.3390/biomedicines10010171.
Humoral Immune Response in IBD Patients Three and Six Months after Vaccination with the SARS-CoV-2 mRNA Vaccines mRNA-1273 and BNT162b2
Richard Vollenberg[SUP] 1 [/SUP], Phil-Robin Tepasse[SUP] 1 [/SUP], Joachim Ewald Kühn[SUP] 2 [/SUP], Marc Hennies[SUP] 2 [/SUP], Markus Strauss[SUP] 3 [/SUP], Florian Rennebaum[SUP] 1 [/SUP], Tina Schomacher[SUP] 1 [/SUP], Göran Boeckel[SUP] 4 [/SUP], Eva Lorentzen[SUP] 2 [/SUP], Arne Bokemeyer[SUP] 5 [/SUP], Tobias Max Nowacki[SUP] 1 6 [/SUP]
Affiliations
- PMID: 35052849
- DOI: 10.3390/biomedicines10010171
Abstract
Severe acute respiratory syndrome coronovirus-2 (SARS-CoV-2) is the cause of the coronavirus disease 2019 (COVID-19) pandemic. Vaccination is considered the core approach to containing the pandemic. There is currently insufficient evidence on the efficacy of these vaccines in immunosuppressed inflammatory bowel disease (IBD) patients. The aim of this study was to investigate the humoral response in immunosuppressed IBD patients after COVID-19 mRNA vaccination. In this prospective study, IgG antibody levels (AB) against the SARS-CoV-2 receptor-binding domain (spike-protein) were quantitatively determined. For assessing the potential neutralizing capacity, a SARS-CoV-2 surrogate neutralization test (sVNT) was employed in IBD patients (n = 95) and healthy controls (n = 38). Sera were examined prior to the first/second vaccination and 3/6 months after second vaccination. Patients showed lower sVNT (%) and IgG-S (AU/mL) AB both before the second vaccination (sVNT p < 0.001; AB p < 0.001) and 3 (sVNT p = 0.002; AB p = 0.001) and 6 months (sVNT p = 0.062; AB p = 0.061) after the second vaccination. Although seroconversion rates (sVNT, IgG-S) did not differ between the two groups 3 months after second vaccination, a significant difference was seen 6 months after second vaccination (sVNT p = 0.045). Before and three months after the second vaccination, patients treated with anti-tumor necrosis factor (TNF) agents showed significantly lower AB than healthy subjects. In conclusion, an early booster shot vaccination should be discussed for IBD patients on anti-TNF therapy.
Keywords: COVID-19; IBD patients; SARS-CoV-2; seroconversion; vaccination.